Eli Lilly Q2 FY25: where the revenue came from and where it went
The whole income statement of Eli Lilly for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Apr 1 – Jun 30, 2025
- Reported
- Aug 7, 2025
Revenue$15.6B
+38% year over year
Gross profit$13.1B
84% margin
Operating profit$6.9B
44% margin
Net profit$5.7B
36% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 15.6 | 100% | +38% |
| Mounjaro | 5.2 | 33% | +68% |
| Zepbound | 3.4 | 22% | +172% |
| Other revenue | 1.6 | 11% | |
| Verzenio | 1.5 | 10% | +12% |
| Trulicity | 1.1 | 7% | −12% |
| Cardiometabolic health | 1.0 | 6% | −16% |
| Other oncology | 0.9 | 6% | +12% |
| Taltz | 0.8 | 5% | +3% |
| Cost of revenue | −2.4 | 16% | |
| Gross profit | 13.1 | 84% margin | +3pp |
| SG&A | −2.8 | 18% | −1pp |
| Other | −3.5 | 22% | +0pp |
| Operating profit | 6.9 | 44% margin | +11pp |
| Interest & other costs | −0.1 | ||
| Tax | −1.1 | ||
| Net profit | 5.7 | 36% margin | +10pp |
123 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest